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About half of people with trisomy 21 have a congenital heart defect (CHD), whereas the remainder have a structurally normal heart,
demonstrating that trisomy 21 is a significant risk factor but is not causal for abnormal heart development. Atrioventricular septal defects
(AVSD) are the most commonly occurring heart defects in Down syndrome (DS), and ~65% of all AVSD is associated with DS. We used
a candidate-gene approach among individuals with DS and complete AVSD (cases¼ 141) and DS with no CHD (controls¼ 141) to deter-
mine whether rare genetic variants in genes involved in atrioventricular valvuloseptal morphogenesis contribute to AVSD in this
sensitized population. We found a significant excess (p < 0.0001) of variants predicted to be deleterious in cases compared to controls.
At themost stringent level of filtering, we found potentially damaging variants in nearly 20% of cases but fewer than 3% of controls. The
variants with the highest probability of being damaging in cases only were found in six genes: COL6A1, COL6A2, CRELD1, FBLN2, FRZB,
and GATA5. Several of the case-specific variants were recurrent in unrelated individuals, occurring in 10% of cases studied. No variants
with an equal probability of being damaging were found in controls, demonstrating a highly specific association with AVSD. Of note, all
of these genes are in the VEGF-A pathway, even though the candidate genes analyzed in this study represented numerous biochemical
and developmental pathways, suggesting that rare variants in the VEGF-A pathway might contribute to the genetic underpinnings of
AVSD in humans.Introduction
Congenital heart defects (CHD) are the most common
form of birth defect, occurring in nearly 1 in 100 live
births.1 There is clear evidence for a significant genetic
contribution to most congenital heart malformations;
however, our understanding of the specific genes involved
in the majority of CHD is limited. On the other hand, our
knowledge of the genetic control of heart development has
grown exponentially over the past few decades, yielding
a wealth of information about the genes responsible for
the exquisitely orchestrated cascade of events that result
in the formation of the vertebrate four-chambered heart.2
Clearly, defects in any number of these genes could lead
to a heart malformation, yet numerous studies to date
have failed to show a significant contribution from some
of the most promising candidate genes to the cause of
heart defects in humans.3–5 However, studies of CHD are
often done with phenotypically heterogeneous cohorts,
which might dilute the power to detect specific associa-
tions with genetic variants.
Atrioventricular septal defect (AVSD [MIM 606215]), also
known as common atrioventricular (AV) canal or endocar-
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Center on Birth Defects and Developmental Disabilities
found that the birth incidence for nonsyndromic AVSD
is 0.83/10,000 live births,6 and the estimated incidence
for all AVSD is 3–5/10,000 live births.7 AVSD is found
most often in children with Down syndrome (DS [MIM
190685]), who account for approximately 65% of all
AVSD cases.8 Among those with DS, about 18% have
a complete AVSD.9 Thus, compared to the euploid popu-
lation, individuals with DS have about a 2,000-fold-
increased risk of AVSD. Although having three copies of
chromosome 21 genes certainly contributes to this risk,
the increased gene dosage itself is not sufficient to cause
the defect. Indeed, half or more of those with DS have
a structurally normal heart. Clearly, other factors in addi-
tion to trisomy 21 are required for causing AVSD in chil-
dren with DS.
The identification of gene mutations and potentially
damaging rare variants associated with familial AVSD
suggests that the risk factors for AVSD in DS might in-
clude variants in heart-development genes that are not
necessarily on chromosome 21.10–12 To date, the gene
most frequently associated with AVSD is CRELD1 (MIM
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identified in a small cohort of simplex AVSD cases,12 with
subsequent identification of additional mutations in indi-
viduals with DS-associated AVSD.13 One of those muta-
tions, c.985C>T (p.Arg329Cys, RefSeq accession number
NM_001077415.2), is recurrent and has been identi-
fied in multiple unrelated individuals with AVSD.12,13
Numerous additional studies have shown that CRELD1
mutations are specifically associated with the AVSD pheno-
type and have been found in several different ethnic and
racial groups.3,14–17 It is estimated that approximately 5%
of individuals with nonsyndromic AVSD carry a CRELD1
missense mutation. Incomplete penetrance has been
demonstrated for many of the mutations, indicating that
deleterious CRELD1 mutations function as risk factors for
AVSD but can be maintained in the general population
as benign variants.
Missense mutations in GATA4 (MIM 600576) have also
been shown to cause cardiac septal defects in humans,
including AVSD in rare families with autosomal-dominant
inheritance of CHD.11,18 Mutations in GATA4 are in-
frequently associated with simplex AVSD cases,16,19,20
although inheritance from unaffected parents indicates
that additional risk factors are required for causing the
defect. Rare variants in ALK2 (ACVR1 [MIM 102576])
have also been associated with CHD, including one case
of an individual with DS and a partial AVSD, otherwise
known as an ostium primum atrial septal defect.21 Addi-
tional ALK2 variants have been identified in individuals
within the AVSD clinical spectrum, although these have
been found in only a very small percentage of cases
analyzed.22 Functional analyses support a role for these
uncommon variants contributing to the risk of heart
defects. Additional rare variants in other genes have been
identified in a small number of AVSD cases; however, their
pathogenicity remains uncertain.23 Onemutation in TBX5
(MIM 601620) was identified in an individual with AVSD
and Holt-Oram syndrome (MIM 142900).24 Somatic muta-
tions in TBX5 and NKX2.5 (MIM 600584) have been iden-
tified in formalin-fixed hearts from deceased individuals
with AVSD and other congenital heart malformations,
including individuals with DS and AVSD,25,26 suggesting
a potentially pathogenic role for nongermline events in
CHD. However, other studies of fresh-frozen tissue from
similarly malformed hearts failed to replicate these find-
ings.27,28 Overall, the mutations associated with AVSD
have been found in only a small proportion of affected
individuals, indicating involvement of additional, as-yet-
unidentified genes.
To advance our knowledge of the genetic basis for AVSD,
we have employed the strategy of studying individuals
with DS as a population sensitized to the actions of addi-
tional genetic risk factors, including genetic variants on
chromosome 21 and on other chromosomes. Our premise
is that the 2,000-fold increase in risk for developing an
AVSD due to trisomy 21 unmasks additional modifiers,
making it possible to detect them in a smaller cohort
than for the euploid population. We hypothesize thatThe Americrare genetic variants, incompletely penetrant on a euploid
background, act synergistically with trisomy 21 to increase
risk for AVSD. Under this model, we focus on rare nonsy-
nonymous coding variants as being the most likely disease
candidates, an approach that has been successful in identi-
fying causative genes for Mendelian disorders via whole-
exome sequencing.29Subjects and Methods
Study Participants
Study participants were recruited from centers across the United
States under protocols approved by the institutional review boards
for each participating center and with informed consent from
a custodial parent for each subject. Recruitment and enrollment
methods have been extensively documented through several
earlier studies.9,30,31 Individuals enrolled in the study had a diag-
nosis of full trisomy 21, with the vast majority confirmed by
a karyotype. Individuals with partial or mosaic trisomy 21 were
not enrolled. A single cardiologist (K.J.D.) reviewed medical
records and classified cases as individuals with DS who had
a complete, balanced AVSD documented by echocardiogram
(DSþAVSD) and controls as individuals with DS who had a docu-
mented structurally normal heart (DS without CHD). Individuals
with patent ductus arteriosus and patent foramen ovale were
allowed as controls. The majority of the samples included in this
sequencing analysis were self-identified via maternal question-
naire as non-Hispanic whites (white), although a small subset of
non-Hispanic black (black) and Hispanic white (Hispanic) individ-
uals were also included. Specifically, of the 141 cases, 111 were
white, 25 were black, and 5 were Hispanic. For the 141 controls,
113 were white, 23 were black, and 5 were Hispanic.
Candidate Genes
The 26 candidate genes resequenced in this study and the ratio-
nale for inclusion are shown in Table S1 (available online). In
general, candidate genes for mutation analyses were selected on
the basis of evidence that disruption of gene function could result
in AVSD. Genes involved in multiple pathways and develop-
mental processes were included.
Sequencing
Genomic DNA for all samples was extracted from low-passage lym-
phoblastoid cell lines. Sequencing was performed via the tradi-
tional Sanger method from PCR amplicons targeted to encompass
coding regions of candidate genes and the surrounding exon-
intron boundaries, 30 and 50 untranslated regions (UTRs), and
~2 kb of intergenic sequence up- and downstream of the transcrip-
tion start and endpoints. Eighteen of the genes were resequenced
in 141 cases and 141 controls through the University of Washing-
ton National Heart, Lung, and Blood Institute (NHLBI) Resequenc-
ing and Genotyping Service, D. Nickerson, Director. Eight genes
were resequenced in at least 100 of the same cases, all white,
through the Oregon Clinical Translational Research Institute
(OCTRI) at Oregon Health & Science University, and variants
were genotyped in 100 white controls. One gene, CRELD1, was re-
sequenced in 135 white cases and controls. Samples resequenced
by OCTRI were a subset of the same samples resequenced by the
University of Washington NHLBI Resequencing Center, with
some additional samples included in the CRELD1 study. Variantsan Journal of Human Genetics 91, 646–659, October 5, 2012 647
identified in this study will be deposited into the National Center
for Biotechnology Information Short Genetic Variations database
(dbSNP) in accordance with NHLBI policy.Variant Classification
Variants were classified as noncoding or coding, synonymous,
nonsynonymous, nonsense, insertion, deletion, splicing, and
frameshift. Previously documented variants were identified
through dbSNP, and the reported allele frequencies were compared
to the allele frequencies in this study. Variants were further classi-
fied as case-specific (variants found only in cases), control-specific
(variants found only in controls), or nonspecific (variants found in
both cases and controls).Bioinformatic Analyses
We used the MutPred web application tool to classify missense
variants according to predicted likelihood of being deleterious to
the protein product.32 MutPred is a supervised method based on
protein-structure- and function-derived attributes, as well as
evolutionary information that provides a computed general score
(g) indicating the probability that a given variant is damaging and/
or disease-associated versus neutral through the use of human-
disease and neutral alleles for training. In addition, MutPred
predicts the molecular cause of damage to the protein on the basis
of a gain or loss of structural and functional properties and
provides a p value (p) for each structural or functional prediction.
Hypotheses that specified structural and functional properties of
the protein are affected can then be generated on the basis of
a combination of the general score and the p value. Mutations
are binned according to the relevant hypothesis. Actionable
hypotheses are assigned to variants with scores of g > 0.5 and
p < 0.05. Confident hypotheses refer to variants with g > 0.75
and p < 0.05. Very confident hypotheses refer to variants with
g > 0.75 and p < 0.01. We analyzed all case- and control-specific
missense variants using these parameters to determine which vari-
ants were the most likely to be associated with disease.
In addition, case- or control-associated variants were evaluated
for the potential to disrupt splicing through alteration of
conserved sequences at intron-exon boundaries and intronic
branchpoint consensus sequences.
The nonspecific variants were further analyzed for determina-
tion of whether there were variants that were statistically overrep-
resented in cases or controls.
Lastly, case- or control-associated variants in the 50 UTR were
evaluated for potential disruption of transcription factor binding
sites via a recently developedmethod for predicting disease-associ-
ated functional variants within gene-regulatory regions.33Statistical Methods
The variants found in both cases and controls were analyzed for
determining whether any variants were statistically overrepre-
sented in cases or controls. Case- and control-specific variants
were binned or collapsed in several ways, and comparisons were
made between the case and control groups. Missense variants
were binned on the basis of the three levels of confidence for
hypotheses (i.e., actionable, confident, and very confident). Poten-
tial splicing variants and potential gene-regulatory variants were
also binned.
p values for comparison of total numbers of variants in cases
versus controls were calculated with Fisher’s exact test, reporting
two-sided p values. We used the simplifying assumption that648 The American Journal of Human Genetics 91, 646–659, Octobereach gene was sequenced in exactly 141 cases and 141 controls
in order to perform tests across genes and pathways; sensitivity
analysis to variations in this assumption (e.g., assuming 120
individuals instead of 141) made essentially no difference in the
p values.
Two-tailed Student’s t tests were used for determining whether
the transcriptional activity from GATA5 substitutions in luciferase
assays was significantly different from wild-type; p values <0.05
were considered significant.
Expression Constructs
Case-specific genetic variants inGATA5 (MIM611496, RefSeqNM_
080473.4) with general scores of g > 0.5—c.8A>G (p.Gln3Arg),
c.424T>C (p.Tyr142His), and c.477C>G (p.Phe159Leu)—were
introduced into cDNA clones (OriGene Technologies, Rockville,
MD, USA) with a QuikChange XL Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA,USA) according tomanufacturer’s instruc-
tions. The single-base mutations and the integrity of all constructs
were confirmed through sequencing of both strands.
Dual Luciferase Assay
The luciferase assay was performed with the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI, USA) with the
use of the pLightSwitch-VEGFA promoter plasmid (pLS-VEGFA),
which has the human VEGF-A (MIM 192240) promoter cloned
upstream of the luciferase gene. COS-7 cells were cotransfected
with the expression vectors for wild-type or mutant GATA5, pLS-
VEGFA, and a Renilla luciferase control vector, pGL4.73 (hRluc/
SV40). Empty vector was used separately as a control, and the
Renilla expression served as an internal standard for transfection
efficiency. Cell extracts were prepared 48 hr after transfection
and assayed for luciferase activity. Luciferase-activity values were
corrected for Renilla activity, and the results were reported as 5
SEM, obtained from three separate transfection assays.Results
Resequencing of the 26 candidate genes identified a total
of 2,221 variants, of which 502 were in coding regions
and 1,719 were in noncoding sequences. All variants
were classified according to the nature of the alteration
and binned into DS with AVSD case-specific, DS with no
CHD control-specific, or nonspecific groups.
Noncoding Variants
Noncoding single-nucleotide variants (SNVs), insertions,
or deletions were identified in all 26 candidate genes,
most frequently in introns. None of the variants identified
in introns altered the consensus sequences for known
splicing elements (splice junctions and branchpoint-
defining sequences). With the exception of case- or
control-specific rare variants, none of the variants in
introns had a significant association with cases or controls.
The case-specific and control-specific intronic variants
were not considered further in this study because of the
uncertainty in assessing functional significance.
The 50 UTR regions for each gene were analyzed for vari-
ants with the potential to alter transcription factor binding
sites. Case- or control-specific SNVs in the 50 UTR were5, 2012
uncommon but did occur in ACVR1 (one case), CITED2
(MIM 602937) (two in controls), COL6A3 (MIM 120250)
(one case), CRELD1 (two in cases), CTGF (MIM 121009)
(one control), CYR61 (MIM 602369) (two in cases), FGF2
(MIM 134920) (one case), ROCK1 (MIM 601702) (two in
cases, four in controls), and SHH (MIM 600725) (one
case). None of these rare variants were found in more
than one individual, and none were reported in dbSNP.
Also, none of these 50 UTR variants showed any indication
of changing predicted transcription factor recognition
sites, and they were therefore of unknown consequence.
All other 50UTRSNVswere found inboth cases and controls
and had no significant association with either group.
Details regarding those SNVs can be found in Table S2.
Coding Variants
Coding variants included numerous previously docu-
mented SNVs, small insertions or deletions, and frameshift
variants. None of the previously documented variants
showed significant overrepresentation in cases or controls.
Consequently, we focused on the newly identified variants
for additional analyses.
Only one nonsense SNV was identified; c.3832G>T
(p.Glu1278*), a truncating mutation in exon 30 of
COL18A1 (MIM 120328, RefSeq NM_130444.2), was iden-
tified in a single control sample. We hypothesize that this
truncating variant in COL18A1, a gene located on chromo-
some 21, results in a normal disomic level of expression of
this gene by eliminating expression from the one trisomic
truncating allele.
A previously unreported deletion was also identified in
COL18A1. The 10 bp frameshift deletion at the 30 end of
exon 33, c.4067_4068del, was detected in 69 individuals;
25 cases were heterozygous for the deletion compared to
41 controls (p ¼ 0.03). One case and two controls were
homozygous for the deletion. The variant encodes a trun-
cated protein of 1,441 amino acids, with 85 substituted
amino acids at the C terminus of the predicted protein
product, disrupting the triple-helical (collagenous)domain,
and terminating prior to the NC1 domain that includes the
coding region for endostatin. Although seen in nearly 25%
of our study cohort, this isoform has not been previously
reported. The significant overrepresentation in controls
compared to cases suggests a potentially protective effect.
COL6A3 had a previously undocumented 3 bp deletion
in exon 40, c.8877_8879delTGC (RefSeq NM_004369.2).
The deletion removes a single alanine residue from an
alanine-rich region of the protein. Out of the 282 individ-
uals resequenced for this gene, 24 cases and 26 controls
were heterozygous for the deletion (p ¼ 0.87).
Anotherundocumented3bpdeletion, c.693_695delAGA
(RefSeqNM_007341.2), was identified in exon 6 of SH3BGR
(MIM 602230) and had similar rates of heterozygous
insertion in 89 cases and 96 controls (p ¼ 0.57). The dele-
tion removes a glutamic acid residue from the protein
sequence. Approximately 50% of the amino acids encoded
by this exon are glutamic acid residues, so it appearsThe Americunlikely that the loss of one glutamic acid residue will
have an impact on the protein.
A 3 bp duplication was detected in exon 1 of CRELD2
(MIM 607171) in a single case. The duplication, c.129_
131dupCAG (RefSeq NM_001135101.1), adds a glutamine
residue to the CRELD domain, which is a glutamine-rich
region and is not predicted to have any functional conse-
quence.
The majority of undocumented coding variants identi-
fied in this study were single-nucleotide missense variants.
A total of 238 nonsynonymous SNVs were identified in 21
of the 26 resequenced genes. Five of the genes, BMP2 (MIM
112261), BMP5 (MIM 112265), GATA4, HEY2 (MIM
604674), and WNT9A (MIM 602863), had no missense
variants in either cases or controls, suggesting that these
genes generally have a low tolerance for variation, at least
on the genetic background of trisomy 21.
All missense SNVs were analyzed for indications that
they were common variants. Documented SNPs found in
dbSNP were further evaluated for evidence of overrepre-
sentation in cases compared to controls. There were 63
previously documented SNVs. None were found to have
a significant bias in allele representation. There were 175
SNVs that were not found in dbSNP, which were also eval-
uated for allelic bias in cases compared to controls. Fifty-
eight variants were found exclusively in cases or in
controls; 34 were case-specific and 24were control-specific.
The remaining 117 SNVs were nonspecific and did not
show any significant allelic association with cases com-
pared to controls.
Potentially Damaging Variants
Altogether, 13 of 26 resequenced genes had variants in
either cases or controls that were potentially damaging
according to MutPred analyses (g > 0.5). A total of 34
case-specific missense SNVs were identified in nine genes,
all of which were heterozygous changes (Table 1). Nine
of these were recurrent, i.e., found in more than one unre-
lated affected individual. The other 25 missense variants
were identified in one individual each. No individual
carried more than one of these case-specific variants. In
all, 48 individual cases carried putatively deleterious case-
specific SNVs.
Ten genes had potentially damaging nonsynonymous
variants that occurred exclusively in controls (Table 2).
Six of the ten genes were the same as those that harbored
case-specific damaging missense changes. There were
a total of 24 potentially damaging missense SNVs in
controls, each occurring only once. No control individual
carried more than one of the potentially damaging vari-
ants. Of the genes with unique missense SNVs found in
both cases and controls, all but one had more potentially
damaging variants in the cases. The exception was FBLN2
(MIM 135821), which had two potentially damaging vari-
ants in cases and four in controls.
Sixteen variants affecting the triple-helical domains of
the four collagen genes analyzed were not scored becausean Journal of Human Genetics 91, 646–659, October 5, 2012 649
Table 1. Case-Specific Missense Variants Predicted to be Deleterious
Gene
Nucleotide
Change
Amino Acid
Change
Frequencya
(Race)b
General Score
(Confidence Level)c
Structure or Function Hypotheses
(Probability Scores)
COL6A1d c.350T>C p.Val117Ala 2/141 (W) 0.776 (VC) loss of helix (p ¼ 0.0076), gain of loop
(p ¼ 0.0079), loss of stability (p ¼ 0.0292),
gain of disorder (p ¼ 0.0353), gain of
ubiquitination at p.Lys121 (p ¼ 0.04441)
c.2614C>T p.Arg872Trp 1/141 (B) 0.790 (C) loss of methylation at p.Arg872 (p ¼ 0.0207),
loss of disorder (p ¼ 0.0259), gain of catalytic
residue at p.Arg872 (p ¼ 0.0467)
c.2304G>C p.Gln768His 1/141 (W) 0.537 (A) gain of sheet (p ¼ 0.0016), loss of helix
(p ¼ 0.0017), gain of loop (p ¼ 0.024)
c.2170G>A p.Ala724Thr 1/141 (W) 0.542 (NP) NP
COL6A2d c.2558G>A p.Arg853Gln 1/141 (W) 0.869 (C) gain of ubiquitination at p.Glu851
(p ¼ 0.0354)
c.316G>A p.Glu106Lys 5/141 (W) 0.759 (C) gain of methylation at p.Glu106 (p¼ 0.0122)
c.2528G>A p.Arg843Gln 1/141 (W) 0.635 (NP) NP
c.2182G>A p.Val728Met 1/141 (W) 0.545 (NP) NP
COL6A3 c.8209A>C p.Lys2737Gln 1/141 (W) 0.650 (A) loss of ubiquitination at p.Lys2737
(p ¼ 0.0283), loss of sheet (p ¼ 0.0315),
loss of methylation at Lys2737 (p ¼ 0.0355)
c.1216C>T p.Arg406Cys 1/141 (W) 0.643 (A) gain of sheet (p ¼ 0.0344), loss of helix
(p ¼ 0.0376)
c.3445C>T p.Arg1149Trp 1/141 (W) 0.625 (A) loss of disorder (p ¼ 0.0107)
c.4117G>A p.Ala1373Thr 1/141 (H) 0.543 (A) gain of phosphorylation at p.Ala1373
(p ¼ 0.0412)
c.8236G>A p.Glu2746Lys 1/141 (W) 0.513 (A) gain of ubiquitination at p.Glu2746
(p ¼ 0.0258), loss of sheet (p ¼ 0.0315), gain
of methylation at p.Glu2746 (p ¼ 0.0427)
c.7873G>T p.Asp2625Tyr 1/141 (W) 0.897 (NP) NP
c.3191G>A p.Arg1064Gln 1/141 (W) 0.834 (NP) NP
c.176G>A p.Arg59Gln 1/141 (W) 0.707 (NP) NP
c.4813A>G p.Ile1605Val 1/141 (B) 0.568 (NP) NP
COL18A1d c.4786G>A p.Gly1596Arg 1/141 (B) 0.810 (VC) gain of MoRFe binding (p ¼ 0.0081)
c.331G>A p.Gly111Arg 1/141 (B) 0.835 (C) loss of helix (p ¼ 0.0167), gain of sheet
(p ¼ 0.0266), gain of MoRFe binding
(p ¼ 0.0311)
c.5156C>T p.Ser1719Leu 1/141 (B) 0.603 (A) loss of disorder (p ¼ 0.0152)
c.1051C>T p.Arg351Cys 1/141(W) 0.640 (NP) NP
c.2635G>A p.Asp879Asn 2/141 (W,B) 0.590 (NP) NP
c.142C>G p.Pro48Ala 4/141 (W, W, B, H) 0.578 (NP) NP
c.1777G>A p.Val593Met 1/141 (W) 0.554 (NP) NP
CRELD1 c.985C>T p.Arg329Cys 2/135 (W) 0.860 (validated) NP; biochemical analysis shows misfolding
c.1240G>A p.Glu414Lys 1/135 (W) 0.798 (VC) gain of methylation (p ¼ 0.016), gain of
MoRF binding (p ¼ 4 3 1004)
CRELD2 c.287C>T p.Ala96Val 3/100 (W) 0.643 (NP) NP
FBLN2 c.3116T>C p.Ile1039Thr 1/141 (W) 0.696 (A) loss of stability (p ¼ 0.0211)
c.2749G>A p.Gly917Ser 1/141 (W) 0.577 (NP) NP
FRZB c.299T>C p.Glu100Ser 1/141 (W) 0.543 (A) gain of disorder (p ¼ 0.0078)
c.695G>A p.Arg232Gln 2/141 (W) 0.634 (NP) NP
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Table 1. Continued
Gene
Nucleotide
Change
Amino Acid
Change
Frequencya
(Race)b
General Score
(Confidence Level)c
Structure or Function Hypotheses
(Probability Scores)
GATA5 c.8A>G p.Gln3Arg 2/141 (W) 0.712 (C; validated) gain of MoRFe binding (p ¼ 8 3 1004),
gain of methylation (p ¼ 0.0283);
transcription assay shows gain of function
c.424T>C p.Tyr142His 1/141(W) 0.743 (A) gain of disorder (p ¼ 0.0409)
c.477C>G p.Glu159Leu 2/141(W, B) 0.754 (NP) NP
The cDNA positions for the nucleotide changes are based on the following reference sequences: COL6A1, NM_001848.2; COL6A2, NM_001849.3; COL6A3,
NM_004369.2; COL18A1, NM_130444.2; CRELD1, NM_001077415.2; CRELD2, NM_001135101.1; ; FBLN2, NM_001004019.1; FRZB, NM_001463.2; and
GATA5, NM_080473.4.
aFrequency is the number of individuals in which each variant was identified over the number of total cases resequenced for that gene.
bRace codes are as follows: W, white; B, black; and H, Hispanic.
cConfidence levels are as follows: A, actionable hypotheses; C, confident hypotheses; VC, very confident hypotheses; and NP, none predicted.
dGene is located on chromosome 21 (trisomic for this population).
eGain of MoRF binding represents gain of molecular recognition factor binding (interaction with other molecules is enhanced).MutPred does not provide reliable predictions for those
sequences. These amino acid substitutions all occurred in
variable positions of the triple-helical domains. Impor-
tantly, none altered the conserved glycine residue of the
Gly-X-Y consensus sequence (X is any amino acid; Y is
hydroxyl-proline or hydroxyl-lysine). These are known
hot spots for disease-associated mutations in collagen
genes, because the glycine residue is the only amino acid
compatible with triple-helical formation.34 Because the
variants identified were in the X position, they are consid-
ered probably benign.
Overall, 24 individual controls carried putatively delete-
rious control-specific SNVs compared to the 48 individual
cases that carried damaging case-specific mutations (p ¼
0.0016).
Examination of Case- and Control-Specific Missense
Variants by Hypothesis Binning
One of the valuable aspects of MutPred is its ability
to generate hypotheses regarding the functional conse-
quences of mutations and assign a probability score to
these predicted properties. Variants can therefore be classi-
fied by combination of the general score and property
scores. MutPred combined scores are binned into three
categories: actionable hypotheses (g> 0.5, p< 0.05), confi-
dent hypotheses (g > 0.75, p < 0.05), and very confident
hypotheses (g > 0.75, p < 0.01). Using these criteria, we
further filtered case- and control-specific variants, elimi-
nating those that did not fall into one of these categories.
At this level of filtering, 15 variants were eliminated from
the case-specific group, leaving 19 high-probability vari-
ants among 26 of the 141 cases (18.4% of cases) in eight
different genes (Table 3). Fifteen variants were removed
from the control-specific group, leaving only nine high-
probability variants among 141 control individuals (6.4%
of controls) and six genes. This resulted in the elimination
of COL6A1 (MIM 120220) and GATA5 from the control-
specific variant list, because there were only case-specific
high-probability variants in those genes when binned by
these criteria (Table 4). Accordingly, there was a significantThe Americexcess of variants predicted to be deleterious in cases
(26/141) compared to controls (9/141) (p ¼ 0.0013).
Examination of SNVs by Race and/or Ethnic Group
The case and control cohorts were largely non-Hispanic
white, but there were some black (25 cases, 23 controls)
and Hispanic (5 cases, 5 controls) individuals included in
the resequencing.We removed variants that were exclusive
to black and Hispanic samples from consideration to deter-
mine whether those genotypes had a significant impact on
the data. Recurrent rare variants that were identified in
whites and other race and/or ethnic groups were retained
in the data set. For missense variants with a general score
g > 0.5, there were case-specific variants in nine genes,
with a total of 28 variants in 42 of the 111 white cases,
whereas control-specific variants were found in eight
genes, with a total of 13 variants in 13 of the 113 white
controls (p < 0.0001). For missense variants that met the
more stringent criteria of actionable, confident, or very
confident hypotheses (Table S3), there were case-specific
variants in eight genes, with 14 variants found in 21
different individuals. Control-specific variants were found
in only two genes, COL6A3 and COL18A1, with three vari-
ants in three individuals (Table S4), although these two
genes have both case- and control-specific variants at this
level of filtering. In summary, in the total data set there
was a significant excess of deleterious missense variants
in nearly 19% (21/111) of white cases, but only 2.6% (3/
113) of controls (p < 0.0001). Consequently, we conclude
that the small amount of race and/or ethnic group hetero-
geneity did not falsely inflate the finding that there is an
excess of deleterious mutations in cases versus controls.
Inheritance of Recurrent Variants
The highest-probability case-specific variants included four
recurrent variants, in COL6A1, COL6A2 (MIM 120240),
CRELD1, and GATA5, which were each identified in more
than one unrelated individual (Table 3). DNA from biolog-
ical parents was resequenced for determination of whether
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Table 2. Control-Specific Missense Variants Predicted to be Deleterious
Gene
Nucleotide
Change
Amino Acid
Change
Frequencya
(Race)b
General Score
(Confidence Level)c
Structure or Function Hypotheses
(Probability Scores)
CITED2 c.792G>T p.Gln264His 1/141 (W) 0.512 (NP) NP
COL6A1d c.3001A>C p.Ser1001Arg 1/141 (W) 0.568 (NP) NP
COL6A2d c.3029T>G p.Phe1010Cys 1/141 (W) 0.814 (NP) NP
c.1129C>T p.Arg377Cys 1/141 (B) 0.566 (A) loss of MoRFe binding (p ¼ 0.0068),
loss of methylation at Arg377 (p ¼ 0.0139)
c.1336G>A p.Asp446Asn 1/141 (B) 0.511 (NP) NP
COL6A3 c.2180A>C p.Tyr727Ser 1/141 (W) 0.769 (C) gain of disorder (p ¼ 0.0248)
c.1688A>G p.Asp563Gly 1/141 (W) 0.760 (NP) NP
c.4090G>A p.Val1364Met 1/141 (B) 0.686 (NP) NP
c.2666G>A p.Arg889His 1/141 (W) 0.601 (NP) NP
c.4561G>A p.Glu1521Lys 1/141 (H) 0.569 (A) gain of MoRFe binding (p ¼ 0.0014),
gain of methylation at Glu1521 (p ¼ 0.0144),
loss of ubiquitination at Lys1518 (p ¼ 0.0272)
c.6263C>T p.Pro2088Leu 1/141 (B) 0.516 (A) gain of MoRFe binding (p ¼ 0.043)
c.2794G>T p.Ala932Ser 1/141 (W) 0.515 (A) gain of disorder (p ¼ 0.0218)
COL18A1d c.373G>A p.Val125Ile 1/141 (B) 0.714 (NP) NP
c.1264C>T p.Arg422Cys 1/141 (H) 0.554 (NP) NP
c.3637C>T p.Arg1213Trp 1/141 (W) 0.610 (A) loss of methylation at Arg1213 (p ¼ 0.007)
CTGF c.172C>G p.Arg58Gly 1/141 (W) 0.709 (NP) NP
FBLN2 c.2770A>C p.Asn924His 1/141 (W) 0.909 (NP) NP
c.2630C>T p.Thr877Met 1/141 (W) 0.776 (NP) NP
c.2658C>A p.Asn886Lys 1/141 (B) 0.615 (C) gain of methylation at Asn886 (p ¼ 0.0045),
gain of catalytic residue at Asn886 (p ¼ 0.007),
gain of ubiquitination at Asn886 (p ¼ 0.0452)
c.3467C>T p.Ala1156Val 1/141 (W) 0.610 (NP) NP
GATA5 c.83C>T p.Ala28Val 1/141 (B) 0.707 (NP) NP
TBX20 c.461C>G p.Pro154Arg 1/141 (B) 0.718 (C) gain of MoRFe binding (p ¼ 3e-04),
loss of ubiquitination at Lys158 (p ¼ 0.0395)
VTN c.728T>C p.Ile243Thr 1/141 (W) 0.718 (NP) NP
c.1267G>A p.Asp423Asn 1/141 (B) 0.532 (C) loss of sheet (p ¼ 0.0126), loss of loop (p ¼ 0.0374)
The cDNA positions for the nucleotide changes are based on the following reference sequences: CITED2, NM_006079.3; COL6A1, NM_001848.2; COL6A2,
NM_001849.3; COL6A3, NM_004369.2; COL18A1, NM_130444.2; CTGF, NM_001901.2; FBLN2, NM_001004019.1; GATA5, NM_080473.4; TBX20,
NM_001077653.1; and VTN, NM_000638.3.
aFrequency is the number of individuals in which each variant was identified over the number of total cases resequenced for that gene.
bRace codes are as follows: W, white; B, black; and H, Hispanic.
cConfidence levels are as follows: A, actionable hypotheses; C, confident hypotheses; VC, very confident hypotheses; and NP, none predicted.
dGene is located on chromosome 21 (trisomic for this population).
eGain of MoRF binding represents gain of molecular recognition factor binding (interaction with other molecules is enhanced).of the recurrent variants were inherited as a single copy
from a parent in all cases except one. The COL6A2
c.316G>A (p.Glu106Lys) variant appears to have occurred
as a de novo mutation in one individual, but was inherited
from a parent in the other four cases. Therewas no bias as to
the gender of the parent of origin for inherited variants.
Alteration of GATA5 Activity by Functional Variants
GATA5 activity was measured for the three case-specific
amino acid substitutions, p.Gln3Arg, p.Tyr142His, and652 The American Journal of Human Genetics 91, 646–659, Octoberp.Phe159Leu, with the use of a luciferase reporter assay
with the luciferase gene under the control of the VEGF-A
promoter. VEGF-A is a known transcriptional target of
GATA5 and an important regulator of AV cushionmorpho-
genesis.35 The most significant functional-hypothesis
score was the case-specific variant, GATA5 c.8A>G
(p.Gln3Arg), which was identified in two unrelated AVSD
cases. The functional prediction indicated enhanced
binding of the p.Arg3 substitution to its DNA targets (p ¼
8 3 1004). The p.Arg3 substitution showed significantly5, 2012
Table 3. Case-Specific Variants with Actionable Hypotheses
Gene Protein Variant
Frequencya
(Race)b
General Score
(Confidence Level)c Structure or Function Hypotheses (Probability Scores)
COL6A1d p.Val117Ala 2/141 (W) 0.776 (VC) loss of helix (p ¼ 0.0076), gain of loop (p ¼ 0.0079), loss of stability (p ¼ 0.0292),
gain of disorder (p ¼ 0.0353), gain of ubiquitination at Lys121 (p ¼ 0.04441)
p.Arg872Trp 1/141 (B) 0.790 (C) loss of methylation at Arg872 (p ¼ 0.0207), loss of disorder (p ¼ 0.0259),
gain of catalytic residue at Arg872 (p ¼ 0.0467)
p.Gln768His 1/141 (W) 0.537 (A) gain of sheet (p ¼ 0.0016), loss of helix (p ¼ 0.0017), gain of loop (p ¼ 0.024)
COL6A2d p.Arg853Gln 1/141 (W) 0.869 (C) gain of ubiquitination at Lys851 (p ¼ 0.0354)
p.Glu106Lys 5/141 (W) 0.759 (C) gain of methylation at Glu106 (p ¼ 0.0122)
COL6A3 p.Lys2737Gln 1/141 (W) 0.650 (A) loss of ubiquitination at Lys2737 (p ¼ 0.0283), loss of sheet (p ¼ 0.0315),
loss of methylation at Lys2737 (p ¼ 0.0355)
p.Arg406Cys 1/141 (W) 0.643 (A) gain of sheet (p ¼ 0.0344), loss of helix (p ¼ 0.0376)
p.Arg1149Trp 1/141 (W) 0.625 (A) loss of disorder (p ¼ 0.0107)
p.Ala1373Thr 1/141 (H) 0.543 (A) gain of phosphorylation at Ala1373 (p ¼ 0.0412)
p.Glu2746Lys 1/141 (W) 0.513 (A) gain of ubiquitination at Glu2746 (p ¼ 0.0258), loss of sheet (p ¼ 0.0315),
gain of methylation at Glu2746 (p ¼ 0.0427)
COL18A1d p.Gly1596Arg 1/141 (B) 0.810 (VC) gain of MoRFe binding (p ¼ 0.0081)
p.Gly111Arg 1/141 (B) 0.835 (C) loss of helix (p ¼ 0.0167), gain of sheet (p ¼ 0.0266),
Gain of MoRF binding (p ¼ 0.0311)
p.Ser1719Leu 1/141 (B) 0.603 (A) loss of disorder (p ¼ 0.0152)
CRELD1 p.Arg329Cysb 2/135 (W) 0.860 (NP) NP; biochemical analysis shows misfolding
p.Glu414Lys 1/135 (W) 0.798 (VC) gain of methylation (p ¼ 0.016), gain of MoRF binding (p ¼ 4 3 1004)
FBLN2 p.Ile1039Thr 1/141 (W) 0.696 (A) loss of stability (p ¼ 0.0211)
FRZB p.Phe100Ser 1/141 (W) 0.543 (A) gain of disorder (p ¼ 0.0078)
GATA5 p.Gln3Argb 2/141 (W) 0.712 (C) gain of MoRFe binding (p ¼ 8 3 1004), gain of methylation (p ¼ 0.0283);
transcription assay shows gain of function
p.Tyr142His 1/141(W) 0.743 (A) gain of disorder (p ¼ 0.0409)
aFrequency is the number of individuals in which each variant was identified over the number of total cases resequenced for that gene.
bRace codes are as follows: W, white; B, black; and H, Hispanic.
cConfidence levels are as follows: A, actionable hypotheses; C, confident hypotheses; VC, very confident hypotheses; and NP, none predicted.
dGene is located on chromosome 21 (trisomic for this population).
eGain of MoRF binding represents gain of molecular recognition factor binding (interaction with other molecules is enhanced).more activity 48 hr after transfection, with a >2-fold
increase in the signal from the VEGF luciferase reporter
compared to wild-type (Figure 1). The relative activity of
p.Arg3 compared to p.Gln3 correlated well with the
MutPred prediction of increased molecular recognition
factor (MoRF) binding by p.Arg3. In comparison, the recur-
rent p.Phe159Leu substitution showed significantly lower
activity compared to wild-type GATA5. Although this
c.477C>G (p.Phe159Leu) variant had the highest general
score of the GATA5 variants, it did not trigger functional
hypotheses by MutPred. The p.Tyr142His substitution
showed activity levels that trended higher than wild-type
but did not reach statistical significance.Discussion
The search for genetic modifiers of risk for CHD is often
challenged by the lack of availability of sufficiently largeThe Americand phenotypically homogeneous study cohorts. Benson
and Martin recently estimated that a sample size of 5,000
would be required for a 1:1 case-control study to detect
a 40% increase in risk for a trait that occurs in 1% of the
population.36 To address this problem, we chose to study
individuals with DS, a sensitized population with a single
highly penetrant risk factor for heart defects. The 2,000-
fold increase in risk for developing an AVSD due to trisomy
21 should make it possible to detect disease-associated
genetic variants in a smaller cohort than for the euploid
population. However, even in a sensitized population
that is selected to be homogenous, the ability to predict
which variants are the most likely to confer risk of disease
is of paramount importance. Given the prevalence of rare
variants in the human genome, the potential for spurious
association is high, so analysis requires robust predictions
of functional consequences of variants.
MutPred was selected for bioinformatic evaluation of
missense changes on the basis of a recent comparisonan Journal of Human Genetics 91, 646–659, October 5, 2012 653
Table 4. Control-Specific Variants with Actionable Hypotheses
Gene Protein Variant
Frequencya
(Race)b
General Score
(Confidence Level)c Structure or Function Hypotheses (Probability Scores)
COL6A2d p.Arg377Cys 1/141 (B) 0.566 (A) loss of MoRFe binding (p ¼ 0.0068), loss of methylation at Arg377 (p ¼ 0.0139)
COL6A3 p.Tyr727Ser 1/141 (W) 0.769 (C) gain of disorder (p ¼ 0.0248)
p.Glu1521Lys 1/141 (H) 0.569 (A) gain of MoRFe binding (p ¼ 0.0014), gain of methylation at Glu1521
(p ¼ 0.0144), loss of ubiquitination at Lys1518 (p ¼ 0.0272)
p.Pro2088leu 1/141 (B) 0.516 (A) gain of MoRFe binding (p ¼ 0.043)
p.Ala932Ser 1/141 (W) 0.515 (A) gain of disorder (p ¼ 0.0218)
COL18A1d p.Arg1213Trp 1/141 (W) 0.610 (A) loss of methylation at Arg1213 (p ¼ 0.007)
FBLN2 p.Asn886Lys 1/141 (B) 0.615 (C) gain of methylation at Asn886 (p ¼ 0.0045), gain of catalytic residue at Asn886
(p ¼ 0.007), gain of ubiquitination at Asn886 (p ¼ 0.0452)
TBX20 p.Pro154Arg 1/141 (B) 0.718 (C) gain of MoRFe binding (p ¼ 3 3 1004), loss of ubiquitination at Lys158
(p ¼ 0.0395)
VTN p.Asp423Asn 1/141 (B) 0.532 (C) loss of sheet (p ¼ 0.0126), loss of loop (p ¼ 0.0374)
aFrequency is the number of individuals in which each variant was identified over the number of total cases resequenced for that gene.
bRace codes are as follows: W, white; B, black; and H, Hispanic.
cConfidence levels are as follows: A, actionable hypotheses; C, confident hypotheses; VC, very confident hypotheses; and NP, none predicted.
dGene is located on chromosome 21 (trisomic for this population).
eGain of MoRF binding represents gain of molecular recognition factor binding (interaction with other molecules is enhanced).between several computational methods that demon-
strated its superior performance inmaking accurate predic-
tions compared to other commonly used algorithms.37
MutPred has the added advantage of providing functional
hypotheses with probability scores, which aids in priori-
tizing follow-up studies. Using a carefully phenotyped,
sensitized population to identify genetic risk factors for
AVSD and rigorous evaluation of genetic variants, we
show that there is an excess of potentially damaging
missense variants in DSþAVSD cases compared to DS
without CHD controls. In our most stringent analysis,
including filtering on the basis of strict functional criteria
and limiting the analysis to white non-Hispanic individ-
uals, we found highly probable deleterious missense vari-
ants in 15% of cases and none in controls (p < 0.0001).
It was notable that the two genes, COL6A3 and
COL18A1, with actionable and confident variants in
controls, also had variants in cases, suggesting a potential
lack of specificity for AVSD. If we consider genes that
have only case- or control-specific variants at this level of
filtering, it would remove all of the genes in the control-
specific group but leave six genes in the case-specific group,
with 10 variants in 17 individuals. These variants were
restricted to six out of the 26 genes investigated,
COL6A1, COL6A2, CRELD1, FBLN2, FRZB (MIM 605083),
and GATA5. Inclusion of all variants in these genes with
a significant general score (g > 0.5) resulted in a total of
17 missense variants in 25 different individuals, or 18%
of all cases. Other genes, including CRELD2, COL6A3,
and COL18A1, also had more potentially deleterious vari-
ants in cases compared to controls. Some of these variants
could well be pathogenic but will be of lower priority for
follow-up studies. In addition, most of the COL18A1
variants were found in black or Hispanic individuals,654 The American Journal of Human Genetics 91, 646–659, Octoberwhich might reflect specific variation in those popula-
tions. Control-specificmissensemutations with significant
general scores were also identified, albeit at a much lower
rate than case-specific mutations. Many of these occurred
in genes that also harbored case-specific variants, but
some genes had variants exclusively in controls, including
CITED2, CTGF, TBX20 (MIM 606061), and VTN (MIM
193190). Control-specific variants could represent protec-
tive alleles, although the low frequencymight also indicate
spurious association.
This study indicates that a significant proportion of
AVSD risk in our study cohort might be attributable to
rare, highly deleterious variants in six genes: COL6A1,
COL6A2, CRELD1, FBLN2, FRZB, and GATA5. With the
exception of CRELD1, all of the high-probability muta-
tions are in genes that have not been previously associated
with AVSD, although COL6A1 and COL6A2 have been
implicated in CHD in DS.38–41 The recurrence of case-
specific variants in the COL6A1, COL6A2, CRELD1, and
GATA5 genes in unrelated individuals provides additional
support for the premise that these genes are involved in
AVSD etiology, especially considering that there were no
recurrent variants specific to controls. One of those vari-
ants, the c.985C>T (p.Arg329Cys) mutation in CRELD1,
has been associated with AVSD in studies across different
syndromic and nonsyndromic populations.12,13 It had
a highly significant general score (g ¼ 0.860), but no
predicted structure or function hypotheses in MutPred.
However, we showed previously that the p. Arg329Cys
substitution, which we predicted would disrupt the
disulfide bonding pattern of an epidermal growth factor
(EGF) domain, does indeed affect protein folding.12
Further, a null allele of Creld1, which has no heart or other
phenotype on a disomic background in a mouse model,5, 2012
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Figure 1. The Transcriptional Activation Ability of GATA5 Vari-
ants as Measured with a Luciferase Assay
COS-7 cells were transfected with VEGF-A promoter-reporter
construct and either wild-type GATA5 construct (WT) or one of
the three GATA5 mutant constructs, as described in Subjects and
Methods. Cells were harvested 48 hr posttransfection, and lucif-
erase activity was measured. Reporter-gene activity was quanti-
tated as luciferase activity relative to WT, which was normalized
to a relative luciferase activity value of 1.0. NEG CTRL is the empty
vector. The bars for eachGATA5mutant construct are identified by
the protein variant. Each bar represents a mean 5 SEM of three
individual experiments. *p ¼ 0.004 and **p ¼ 0.0009 (two-tailed
Student’s t test).greatly increases the occurrence of CHD in a mouse model
of DS.42
In this study we identified a previously unreported
variant in GATA5, c.8A>G (p.Gln3Arg), in two individuals.
This change increased activation of transcription, consis-
tent with the highly probable hypothesis that this amino
acid change would result in stronger MoRF binding (p ¼
8 3 1004) predicted by MutPred. The dramatic increase
in GATA5 activation of the VEGF-A promoter indicates
the potential for the p.Arg3 substitution to affect AV
cushion morphogenesis by increasing VEGF-A expression,
which is known to contribute to the cause of CHD in
mouse models.43,44 Another newly identified recurrent
GATA5 variant, c.477C>G (p.Phe159Leu), significantly
decreased GATA5 activity to less than half that of wild-
type. Decreased VEGF-A expression has also been associ-
ated with CHD in mouse models, indicating that this is
also a pathogenic substitution, and that changes that result
in significant increases or decreases in GATA5 activity can
contribute to the etiology of AVSD. There are also recur-
rent variants in COL6A1 and COL6A2. The c.316G>A
(p.Glu106Lys) case-specific variant in COL6A2 was found
in five unrelated individuals. Collectively, in this study
alone we found potentially damaging recurrent variants
in 10% of cases across four genes, and none in controls
(p ¼ 0.0002).
Recurrence of damaging mutations is consistent with
our premise that genetic risk factors for AVSD are present
at a low frequency in the general population. These vari-The Americants are incompletely penetrant and benign in the general
population but contribute to AVSD susceptibility on a
sensitive background.42 Trisomy 21 confers substantial
risk for CHD but still requires additional ‘‘hits’’ to elicit
the defect. Our data indicates that those hits occur as
missense changes in a subset of heart-development genes.
We propose that those same variants confer risk of AVSD in
the non-DS population and that the defect occurs when
a sufficient number of factors combine to breach the
disease threshold. This is supported by our previous studies
showing that the CRELD1 p.Arg329Cys mutation is associ-
ated with both DS-related and nonsyndromic AVSD and is
inherited from an unaffected parent,12,13 as well as our
finding that the other recurrent case-specific variants pre-
sented here are also inherited from unaffected parents.
One finding of particular interest is the apparent in-
volvement of COL6A1 and COL6A2 in DS-related AVSD.
These genes are located together on human chromosome
21q22.3 and are therefore trisomic in DS. COL6A1 and
COL6A2 encode two of the three chains for the heterotri-
meric type VI collagen protein. Variation in these genes
has been implicated in the etiology of CHD in DS through
genetic association studies, although only common vari-
ants were previously considered.38–41 However, the impli-
cations of genetic association between variants in collagen
VI genes and AVSD have never been fully realized. In addi-
tion, abnormal expression of type VI collagen protein has
been shown in DS fetal hearts and correlates with morpho-
logical defects of AV endocardial-derived structures.45 This
has driven further speculation that genetic variation in the
collagen VI genes is somehow associated with AVSD. Most
recently, overexpression of COL6A2 and DSCAM (MIM
602523) from an exogenous a-MHC promoter in trans-
genic mouse hearts has been shown to disrupt heart devel-
opment in doubly transgenic mice.46 In spite of all of the
suggestive data, this is compelling evidence that rare
missense variants in COL6A1 and COL6A2 are specifically
associated with AVSD.
Paradoxically, mutations in COL6A1, COL6A2, and
COL6A3 are known to cause two skeletal muscular dystro-
phies: Bethlem myopathy (MIM 158810) and Ullrich
congenital muscular dystrophy (MIM 254090). Bethlem
myopathy is thought to be autosomal dominant, although
many cases occur sporadically as a result of de novo muta-
tions. Ullrich myopathy is generally autosomal recessive,
with heterozygous carriers being asymptomatic. Cardio-
myopathies and arrhythmias are common in individuals
with Bethlem myopathy, but septal malformations have
not been reported.47 The mutations found in these muscle
diseases are usually deletions, exon skipping, missplicing,
or substitutions for the conserved glycine residues in the
triple-helical domains, although a few other missense vari-
ants have also been associated with the disease.48 By
contrast, the potentially deleterious variants identified in
this study were found exclusively in the coding regions
for the N-terminal and C-terminal globular domains of
COL6A1 and COL6A2. The C-terminal globular domainsan Journal of Human Genetics 91, 646–659, October 5, 2012 655
Table 5. Relationship of AVSD Candidate Genes to VEGF-A
Gene Relationship
COL6A1 expression is responsive to VEGF-A49
COL6A2 expression is responsive to VEGF-A49
CRELD1 modulates cell response to VEGF-A (C.L.M., unpublished data)
FBLN2 downregulates VEFG-A50
FRZB upstream regulator of VEGF-A expression51
GATA5 transcriptional regulation of VEGF-A expression35are required for initial monomer assembly into hetero-
trimers from the chains encoded by COL6A1, COL6A2,
and COL6A3. The N-terminal globular domains participate
in the higher-ordered assembly of collagen VI microfibrils
following folding of the heterotrimers. The AVSD-associ-
ated COL6A1 and COL6A2 variants were inherited from
self-reported phenotypically normal parents, demonstrat-
ing that these are not dominant skeletal myopathy muta-
tions, but might be incompletely penetrant AVSD risk
alleles that are pathogenic on the sensitized trisomy 21
background. If there is an incompletely penetrant or very
mild skeletal phenotype associated with these mutations,
we might not detect it in the parents. It is also possible
that these variants could exacerbate the hypotonia
commonly found in children with DS. However, we do
not have information about the course of hypotonia in
these individuals, so that cannot be assessed. It is also
possible that these variants do not affect skeletal muscle
but are instead specific to the heart. Pleiotropy for collagen
VI genemutations could be due to differences in the nature
of the variants found in heart defects compared to skeletal
muscle abnormalities. Further study of these variants will
significantly advance our understanding of collagen VI
biology. In addition, COL6A1 and COL6A2 are known to
be quite variable in their composition in terms of polymor-
phic missense variants, so the potential for intragenic
allelic interactions is significant. However, we did not
find any specific associations between case- or control-
specific rare variants and nonspecific SNVs, suggesting
that COL6A1 and COL6A2 intragenic allelic interactions
are not significant in DS.
Although we have focused here on missense variants, it
is notable that there are other variants of interest that
deserve follow-up consideration. In particular, the rare
case-specific SNVs in the 50 UTRs of several of the candidate
genes are of unknown consequence but certainly could
have the potential to alter regulation of gene expression.
Additionally, the 10 bp deletion in exon 33 of COL18A1,
which is predicted to truncate the protein, warrants further
investigation. The overrepresentation in controls com-
pared to cases (p < 0.03) suggests a protective effect. The
role of type XVIII collagen in heart development is poorly
understood; therefore, investigation of this variant could
be informative in terms of both the pathogenesis of
AVSD and heart development in general.
Pathway analysis led to the unexpected finding that all
six genes harboring purportedly deleterious case-specific
variants are associated in some way with VEGF-A (Table 5).
VEGF-A is potent mitogen that is a known regulator of
AV valvuloseptal morphogenesis, wherein it is critical
for the formation of the AV endocardial cushions and
helps guide the morphogenesis of those primordial struc-
tures into the AV valves.52,53 In animal models, both in-
creased and decreased levels of VEGF-A expression during
heart development are associated with CHD, including
AVSD.43,44,54,55 Consequently, deleterious mutations in
genes that alter VEGF-A expression or are responsive to656 The American Journal of Human Genetics 91, 646–659, OctoberVEGF-A have a clear developmental link to AVSD, suggest-
ing a mechanism by which the variants identified in this
study could contribute to the pathogenesis of AVSD. How-
ever, the effect of variation in these genes might extend to
other aspects of AV valve development. Although develop-
ment of the AV endocardial cushions is critical to AV septa-
tion, there is also a significant contribution from the
myocardium and from both endothelium- and nonendo-
thelium-derived mesenchyme. The dorsal mesenchymal
protrusion (DMP) is a structure arising from the venous
pole of the heart that is critical to proper AV septation.
Indeed, study of the Tc1 mouse model for DS has led to
speculation that AVSD in DS results from an abnormality
in the DMP.56,57 Although there is no established develop-
mental role for our six genes harboring AVSD-associated
variants in the development of the DMP, it is possible
that they play unknown roles in the formation of that
structure.
In contrast, other genes in our study have direct links to
the DMP, which is derived from the second heart field
(SHF). Our study includes five genes central to the SHF
regulatory network: SHH, BMP4 (MIM 112262), GATA4,
TBX1 (MIM 602054), and TBX20. None of these candidate
genes had any potentially damaging variants in our study
cohort, and, in general, they showed substantially less
genetic variation than many of the other candidate genes.
Of course, this does not rule out involvement of impaired
DMP development in AVSD, and the absence of genetic
variation in these genes suggests that alterations to their
protein products might not be tolerated in DS.
We propose that most or all variants that show additive
effects with trisomy 21 to interfere with heart develop-
ment are the same variants that combine to produce
AVSD in all individuals affected with this CHD. Our study
demonstrates that the recurrent variants identified in 10%
of cases are present as benign variants in the general pop-
ulation and are therefore available to confer risk when
acting in concert with additional factors. The sensitized
DS background provides an increased signal for these
variants, which could be difficult to identify in euploid
individuals with nonfamilial CHD. In this study, no one
individual had more than one deleterious rare variant in
any of these genes, whichmight reflect the very large effect
of trisomy 21. The absence of the predisposing effect of
trisomy 21 would require that a greater number of risk5, 2012
factors, each of smaller effect size, come together to
produce the AVSD phenotype. This is supported by the
significantly lower risk to euploid individuals, indicating
that there is no single AVSD risk factor of large effect size
in the euploid population. We anticipate that all six of
the genes harboring AVSD-associated variants identified
in this study will likewise be associated with AVSD in other
cohorts, as has been seen for the recurrent CRELD1
missense mutation, p.Arg329Cys, which has been identi-
fied in nonsyndromic AVSD, DS-associated AVSD, and
AVSD in heterotaxy syndrome (MIM 606217).
Discovery of AVSD-associated genetic variants in this
study provides insight into the identity of other probable
modifiers. We anticipate that additional mutations in
VEGF-A pathway genes will eventually be implicated in
the pathogenesis of AVSD. In addition, we envision that
allelic interactions between the genes identified and varia-
tion in interacting proteins will have the potential to
furthermodify risk but also to potentially influence pheno-
type and outcomes. This might be particularly true for
AVSD, given that there is evidence that DS-associated
AVSD, which tends to be a common AV canal balanced
between the left and right ventricles, is anatomically
distinct from most euploid AVSD.58 In addition, complete
AVSD is more often an isolated cardiac malformation in DS
than in euploid cases.59 It is possible that the presence of
an extra copy of chromosome 21 drives development
toward that specific outcome, and the presence of addi-
tional risk factors more greatly influences risk of abnormal
heart development than the precise nature of the defect.
Likewise, outcomes might be differentially affected de-
pending on the presence or absence of trisomy 21. In
one study, fetuses with DS and AVSD had a better survival
rate than those with nonsyndromic AVSD, including
a higher rate of successful surgical repair.60
Although there are many possible developmental routes
to AVSD, as indicated by mouse models, the findings in
this study suggest that the VEGF-A pathway could play
a predominant role in the cause of AVSD in DS. However,
candidate-gene studies are by nature biased; thus, addi-
tional studies are required to determine the global role of
the VEGF-A pathway in AVSD. It is thanks to the families
with DS that variations in these genes that contribute to
the most frequent human congenital anomaly are coming
to light.Supplemental Data
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